Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura

OBJECTIVE: To investigate the efficacy and safety of rituximab (RTX) as first-line treatment of acquired thrombotic thrombocytopenic purpura (aTTP). METHODS: Twenty-five patients with acute aTTP and/or severe a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Haifei, Fu, Ailin, Wang, Jing, Wu, Tianqin, Li, Zhengyang, Tang, Jieqing, Shen, Hongshi, Zhu, Jingjing, Li, Jie, Zhu, Qian, Qing, Longmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Clinical Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536423/
https://www.ncbi.nlm.nih.gov/pubmed/28639502
http://dx.doi.org/10.1177/0300060517695646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536423/
https://www.ncbi.nlm.nih.gov/pubmed/28639502
http://dx.doi.org/10.1177/0300060517695646

Ejemplares similares